Pneumonia and Related Conditions in Critically Ill Patients-Insights from Basic and Experimental Studies

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Sep 9

PMID 36077293

Authors

Darya A Kashatnikova

Maryam B Khadzhieva

Dmitry S Kolobkov

Olesya B Belopolskaya

Tamara V Smelaya

Alesya S Gracheva

Ekaterina V Kalinina

Sergey S Larin

Artem N Kuzovlev

Lyubov E Salnikova

Affiliations

Soon will be listed here.

Abstract

Pneumonia is an acute infectious disease with high morbidity and mortality rates. Pneumonia's development, severity and outcome depend on age, comorbidities and the host immune response. In this study, we combined theoretical and experimental investigations to characterize pneumonia and its comorbidities as well as to assess the host immune response measured by TREC/KREC levels in patients with pneumonia. The theoretical study was carried out using the Columbia Open Health Data (COHD) resource, which provides access to clinical concept prevalence and co-occurrence from electronic health records. The experimental study included TREC/KREC assays in young adults (18-40 years) with community-acquired (CAP) ( = 164) or nosocomial (NP) ( = 99) pneumonia and healthy controls ( = 170). Co-occurring rates between pneumonia, sepsis, acute respiratory distress syndrome (ARDS) and some other related conditions common in intensive care units were the top among 4170, 3382 and 963 comorbidities in pneumonia, sepsis and ARDS, respectively. CAP patients had higher TREC levels, while NP patients had lower TREC/KREC levels compared to controls. Low TREC and KREC levels were predictive for the development of NP, ARDS, sepsis and lethal outcome ( in the range 0.71-0.82, in the range 0.67-0.74). TREC/KREC analysis can be considered as a potential prognostic test in patients with pneumonia.

Citing Articles

Prevalence and Antimicrobial Resistance Trends among Lower Respiratory Tract Pathogens in Crete, Greece, 2017-2022.

Maraki S, Mavromanolaki V, Kasimati A, Iliaki-Giannakoudaki E, Stafylaki D Infect Chemother. 2025; 56(4):492-501.

PMID: 39762925 PMC: 11704854. DOI: 10.3947/ic.2024.0060.

Rare Variants in Primary Immunodeficiency Genes and Their Functional Partners in Severe COVID-19.

Khadzhieva M, Kolobkov D, Kashatnikova D, Gracheva A, Redkin I, Kuzovlev A Biomolecules. 2023; 13(9).

PMID: 37759780 PMC: 10526997. DOI: 10.3390/biom13091380.

COVID-19 severity: does the genetic landscape of rare variants matter?.

Khadzhieva M, Gracheva A, Belopolskaya O, Kolobkov D, Kashatnikova D, Redkin I Front Genet. 2023; 14:1152768.

PMID: 37456666 PMC: 10339319. DOI: 10.3389/fgene.2023.1152768.

References

Falci C, Gianesin K, Sergi G, Giunco S, De Ronch I, Valpione S . Immune senescence and cancer in elderly patients: results from an exploratory study. Exp Gerontol. 2013; 48(12):1436-42. DOI: 10.1016/j.exger.2013.09.011. View

Jung D, Alt F . Unraveling V(D)J recombination; insights into gene regulation. Cell. 2004; 116(2):299-311. DOI: 10.1016/s0092-8674(04)00039-x. View

Fine M, Auble T, Yealy D, Hanusa B, Weissfeld L, Singer D . A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997; 336(4):243-50. DOI: 10.1056/NEJM199701233360402. View

Serana F, Chiarini M, Zanotti C, Sottini A, Bertoli D, Bosio A . Use of V(D)J recombination excision circles to identify T- and B-cell defects and to monitor the treatment in primary and acquired immunodeficiencies. J Transl Med. 2013; 11:119. PMC: 3666889. DOI: 10.1186/1479-5876-11-119. View

Ramirez J, Wiemken T, Peyrani P, Arnold F, Kelley R, Mattingly W . Adults Hospitalized With Pneumonia in the United States: Incidence, Epidemiology, and Mortality. Clin Infect Dis. 2017; 65(11):1806-1812. DOI: 10.1093/cid/cix647. View

Vivier E, Malissen B . Innate and adaptive immunity: specificities and signaling hierarchies revisited. Nat Immunol. 2004; 6(1):17-21. PMC: 7097365. DOI: 10.1038/ni1153. View

Smelaya T, Belopolskaya O, Smirnova S, Kuzovlev A, Moroz V, Golubev A . Genetic dissection of host immune response in pneumonia development and progression. Sci Rep. 2016; 6:35021. PMC: 5057148. DOI: 10.1038/srep35021. View

Torres A, Cilloniz C, Niederman M, Menendez R, Chalmers J, Wunderink R . Pneumonia. Nat Rev Dis Primers. 2021; 7(1):25. DOI: 10.1038/s41572-021-00259-0. View

Knaus W, Draper E, Wagner D, Zimmerman J . APACHE II: a severity of disease classification system. Crit Care Med. 1985; 13(10):818-29. View

10.

van Gageldonk-Lafeber A, Bogaerts M, Verheij R, van der Sande M . Time trends in primary-care morbidity, hospitalization and mortality due to pneumonia. Epidemiol Infect. 2009; 137(10):1472-8. DOI: 10.1017/S0950268809002258. View

11.

Ferguson N, Fan E, Camporota L, Antonelli M, Anzueto A, Beale R . The Berlin definition of ARDS: an expanded rationale, justification, and supplementary material. Intensive Care Med. 2012; 38(10):1573-82. DOI: 10.1007/s00134-012-2682-1. View

12.

Salnikova L, Kolobkov D, Sviridova D, Abilev S . An overview of germline variations in genes of primary immunodeficiences through integrative analysis of ClinVar, HGMD and dbSNP databases. Hum Genet. 2021; 140(9):1379-1393. DOI: 10.1007/s00439-021-02316-w. View

13.

Girardot T, Rimmele T, Venet F, Monneret G . Apoptosis-induced lymphopenia in sepsis and other severe injuries. Apoptosis. 2016; 22(2):295-305. DOI: 10.1007/s10495-016-1325-3. View

14.

Heo J, Song J . Disease Burden and Etiologic Distribution of Community-Acquired Pneumonia in Adults: Evolving Epidemiology in the Era of Pneumococcal Conjugate Vaccines. Infect Chemother. 2019; 50(4):287-300. PMC: 6312904. DOI: 10.3947/ic.2018.50.4.287. View

15.

Maca J, Jor O, Holub M, Sklienka P, Bursa F, Burda M . Past and Present ARDS Mortality Rates: A Systematic Review. Respir Care. 2016; 62(1):113-122. DOI: 10.4187/respcare.04716. View

16.

Cuvelier P, Roux H, Couedel-Courteille A, Dutrieux J, Naudin C, Charmeteau de Muylder B . Protective reactive thymus hyperplasia in COVID-19 acute respiratory distress syndrome. Crit Care. 2021; 25(1):4. PMC: 7781174. DOI: 10.1186/s13054-020-03440-1. View

17.

Goggins J, Kurtz J, McLachlan J . Control of Persistent Infection Relies on Constant Thymic Output Despite Increased Peripheral Antigen-Specific T Cell Immunity. Pathogens. 2020; 9(8). PMC: 7459538. DOI: 10.3390/pathogens9080605. View

18.

Gul K, Sonerud T, Fjaerli H, Nakstad B, Abrahamsen T, Inchley C . Thymus activity measured by T-cell receptor excision circles in patients with different severities of respiratory syncytial virus infection. BMC Infect Dis. 2017; 17(1):18. PMC: 5217228. DOI: 10.1186/s12879-016-2148-0. View

19.

. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022; 399(10325):629-655. PMC: 8841637. DOI: 10.1016/S0140-6736(21)02724-0. View

20.

Savchenko A, Tikhonova E, Kudryavtsev I, Kudlay D, Korsunsky I, Beleniuk V . TREC/KREC Levels and T and B Lymphocyte Subpopulations in COVID-19 Patients at Different Stages of the Disease. Viruses. 2022; 14(3). PMC: 8954181. DOI: 10.3390/v14030646. View